References
- Papers of special note have been highlighted as:
- * Of interest
- ** Of considerable interest
- Cancer Research UK. 2013. Cancer research UK [Internet]. [cited 2013 Apr 15]. Available from: http://www.cancerresearchuk.org/
- National Cancer Institute. 2013. National Cancer Institute [Internet]. Available from: www.cancer.gov
- Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol [Internet]. 2011;29(5):487–494. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21220605
- Redaelli A, Botteman MF, Stephens JM, et al. Economic burden of acute myeloid leukemia: a literature review. Cancer Treat Rev [Internet]. 2004;30(3):237–247. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15059647
* This paper presents a literature review performed on the same topic as current manuscript, only then more than 10 years ago.
- Sotak ML, Marin M, Coombs J, et al. PSY19 burden of illness (BOI) of FLT3-mutated acute myeloid leukemia (AML). Value Heal [Internet]. 2012;15(4):A101–A102. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1098301512006183
** One of few studies describing the total burden of AML patients, including both direct and indirect costs.
- Tennvall GR, Persson U, Nilsson B. The economic costs of acute myeloid leukemia in Sweden. Int J Technol Assess Health Care. 1994;10(4):683–694.
** One of few studies describing the total burden of AML patients, including both direct and indirect costs.
- National Institute for Health and Clinical Excellence. Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
** This report of the NICE was used to obtain input data for the calculations of the direct cost of AML treatment for the four patient types as presented in this manuscript.
- Schwarzenbach F, Woronoff-Lemsi MC, Deconinck E, et al. Cost analysis of allogeneic bone marrow transplantation. Hematol Cell Ther. 2000;42(2–3):149–154.
** Cost for transplantation in the presented direct cost of AML treatment calculations was obtained from this paper.
- OECD StatExtracts. Consumer Prices (MEI): Consumer prices - Annual inflation [Internet]. Available from: http://stats.oecd.org/index.aspx?queryid=22519
- X-Rates. 2013. Currency Calculator [Internet]. Available from: http://www.x-rates.com/
- Bradley CJ, Dahman B, Jin Y, et al. Acute myeloid leukemia: how the uninsured fare. Cancer [Internet]. 2011;117(20):4772–4778. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21455994
- El-Zawahry HM, Zeeneldin AA, Samra MA, et al. Cost and outcome of treatment of adults with acute myeloid leukemia at the National Cancer Institute-Egypt. J Egypt Natl Canc Inst [Internet]. 2007;19(2):106–113. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19034340
- Katz LM, Howell JB, Doyle JJ, et al. Outcomes and charges of elderly patients with acute myeloid leukemia. Am J Hematol [Internet]. 2006;81(11):850–857. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16868937
- Lang K, Earle CC, Foster T, et al. Trends in the treatment of acute myeloid leukaemia in the elderly. Drugs Aging [Internet]. 2005;22(11):943–955. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16323971
- Menzin J, Lang K, Earle CC, et al. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med [Internet]. 2002;162(14):1597–1603. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12123403
- Uyl-de Groot CA, Gelderblom-den Hartog J, Huijgens PC, et al. Costs of diagnosis, treatment, and follow up of patients with acute myeloid leukemia in the Netherlands. J Hematother Stem Cell Res [Internet]. 2001;10(1):187–192. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11276372
- Stalfelt AM, Brodin H. Costs over time in conventional treatment of acute myeloid leukaemia. A study exploring changes in treatment strategies over two decades. J Intern Med [Internet]. 1994;236(4):401–409. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7931043
- Stalfelt AM, Brodin H, Wadman B. Cost analysis of different phases of acute myeloid leukaemia. Leuk Res [Internet]. 1994;18(10):783–790. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7934137
- Uyl-de Groot CA, Okhuijsen SY, Hagenbeek A, et al. Costs of introducing autologous BMT in the treatment of lymphoma and acute leukaemia in the Netherlands. Bone Marrow Transplant. 1995;15(4):605–610.
- Nerich V, Lioure B, Rave M, et al. Induction-related cost of patients with acute myeloid leukaemia in France. Int J Clin Pharm [Internet]. 2011;33(2):191–199. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21744189
- Pashko S, Jacobs J, Santorsa J. The cost-effectiveness of idarubicin/cytosine arabinoside versus daunorubicin/cytosine arabinoside in the treatment of adults with acute myeloid leukemia. Clin Ther [Internet]. 1991;13(3):353–360. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1954636
- Walter RB, Lee SJ, Gardner KM, et al. Early discharge and outpatient management of adult patients following intensive induction chemotherapy for MDS and non-APL AML : a pilot study. Blood. 2010;116(21):2161.
- Marie JP, Wdowik T, Bisserbe S, et al. Cost of complete remission induction in acute myeloblastic leukemia: evaluation of the cost-effectiveness of a new drug. Leukemia [Internet]. 1992;6(7):720–722. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1625492
- Lobo PJ, Powles RL, Hanrahan A, et al. Acute myeloblastic leukaemia: a model for assessing value for money for new treatment programmes. BMJ [Internet]. 1991;302(6772):323–326. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1669019&tool=pmcentrez&rendertype=abstract
- Mahmoud D, Skikne BS, Kucmin-bemelmans I, et al. Overall economic burden of total treatment costs in acute myeloid leukemia throughout the course of the disease. Blood. 2012;120(21):3614.
- Clavio M, Quintino S, Masoudi B, et al. Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens. J Exp Clin Cancer Res [Internet]. 2001;20(2):165–173. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11484970
- Huang B-T, Wang Y, Du Q-F, et al. Analysis of efficacy and cost-effectiveness of high-dose arabinoside versus daunorubicin chemotherapy in older adult patients with acute myeloid leukemia by cytogenetic risk profile: retrospective review from China. Int J Hematol [Internet]. 2011;93(4):474–481. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21387092
- Berman E, Little C, Teschendorf B, et al. Financial analysis of patients with newly diagnosed acute myelogenous leukemia on protocol or standard therapy. Cancer [Internet]. 2002;95(5):1064–1070. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12209692
- Uyl-de Groot CA, Löwenberg B, Vellenga E, et al. Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia. Br J Haematol [Internet]. 1998;100(4):629–636. Available from: http://doi.wiley.com/10.1046/j.1365-2141.1998.00635.x
- Yu Y-B, Gau J-P, You J-Y, et al. Cost-effectiveness of postremission intensive therapy in patients with acute leukemia. Ann Oncol [Internet]. 2007;18(3):529–534. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17164232
- Dufoir T, Saux MC, Terraza B, et al. Comparative cost of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission. Bone Marrow Transplant [Internet]. 1992;10(4):323–329. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1422487
- Viens-Bitker C, Fery-Lemonnier E, Blum-Boisgard C, et al. Cost of allogeneic bone marrow transplantation in four diseases. Health Policy [Internet]. 1989;12(3):309–317. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10303779
- Kay HE, Powles RL, Lawler SD, et al. Cost of bone-marrow transplants in acute myeloid leukaemia. Lancet. 1980;1(8177):1067–1069.
- Van Agthoven M, Groot MT, Verdonck LF, et al. Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia. Bone Marrow Transplant. 2002;30(4):243–251.
- Couban S, Dranitsaris G, Andreou P, et al. Clinical and economic analysis of allogeneic peripheral blood progenitor cell transplants: a Canadian perspective. Bone Marrow Transplant [Internet]. 1998;22(12):1199–1205. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9894724
- Shamsi T, Hashmi K, Adil S, et al. The stem cell transplant program in Pakistan: the first decade. Bone Marrow Transplant. 2008;42(Suppl 1):S114–S117.
- Cordonnier C, Maury S, Esperou H, et al. Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia. Bone Marrow Transplant. 2005;36(7):649–654.
- Bennett C, Waters T, Stinson T, et al. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999;24(5):555–560.
- Ngamkiatphaisan S, Sriratanaban J, Kamolratanakul P, et al. Cost analysis of hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia at King Chulalongkorn Memorial Hospital. J Med Assoc Thai. 2007;90(12):2565–2573.
- Imataki O, Kamioka T, Fukuda T, et al. Cost and effectiveness of reduced-intensity and conventional allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Support Care Cancer. 2010;18(12):1565–1569.
- Welch HG, Larson EB. Cost effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. N Engl J Med. 1989;321(12):807–812.
- Barr R, Furlong W, Henwood J, et al. Economic evaluation of allogeneic bone marrow transplantation: a rudimentary model to generate estimates for the timely formulation of clinical policy. J Clin Oncol [Internet]. 1996;14(5):1413–1420. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8622054